Bharat Biotech launches JE vaccine

Genome Valley-based drug maker Bharat Biotech has launched vero cell-derived purified inactivated JE vaccine 'Jenvac', which received the manufacturing and marketing approvals by the Drug Controller General of India (DCGI).

It is a fully indigenous vaccine commercialised using strain, identified, characterised, manufactured and tested in India, the company stated in a press release on Friday.

The uniqueness of Jenvac, according to the company, is its strength to provide increased immunogenicity and long-term protection as a result of unique manufacturing technologies.

The virus strain for the vaccine was isolated in Kolar, Karnataka, during the early 1980s and characterised by the National Institute of Virology, Pune and the strains were transferred to Bharat Biotech for further vaccine development.
 

"Jenvac is a product of years of committed R&D," chairman and managing director of Bharat Biotech, Krishna M Ella, said.